
|Videos|April 14, 2023
Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?
Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
4
AI system links surgical gestures with postoperative outcomes
5














